Contineum’s Phase 2 MOONLIGHT-1 Trial Of JNJ-5120/PIPE-307 Did Not Meet Its Primary Efficacy Endpoint; Analyses Of The Data, Including Prespecified Exploratory Endpoints, Are Ongoing
Key takeaways
- The MOONLIGHT‑1 trial did not meet its main goal, raising questions about JNJ‑5120/PIPE‑307’s clinical promise.
- Primary endpoint: MADRS change at Day 5 vs placebo
- Trial type: randomized, double‑blind, multicenter, placebo‑controlled
- Phase: 2
What happened
Contineum Therapeutics’ Phase 2 MOONLIGHT‑1 trial of JNJ‑5120/PIPE‑307 failed to hit its primary efficacy endpoint, the change in Montgomery‑Åsberg Depression Rating Scale total score at Day 5 versus placebo.
Why it matters
The result signals that the drug may not provide the rapid antidepressant benefit the study aimed for, potentially delaying or altering the development path for this compound under Johnson & Johnson’s license.
Short-term and longer-term
Short-term. Short‑term traders should note that the announcement may trigger a sell‑off in shares as the drug’s rapid‑acting profile is now in doubt.
Longer-term. Long‑term investors should consider the broader implications for Contineum’s pipeline and its partnership with Johnson & Johnson.